FATE Fate Therapeutics Inc

Price (delayed)

$34.14

Market cap

$3.31B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.64

Enterprise value

$3.35B

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer. The Company has established a leadership position in the clinical development and manufacture ...

Highlights
The gross profit has increased by 42% year-on-year and by 8% since the previous quarter
FATE's revenue is up by 42% year-on-year and by 8% since the previous quarter
The company's equity fell by 23% YoY and by 8% QoQ
The net income has contracted by 20% YoY and by 9% from the previous quarter

Key stats

What are the main financial stats of FATE
Market
Shares outstanding
97M
Market cap
$3.31B
Enterprise value
$3.35B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.68
Price to sales (P/S)
48.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
49.13
Earnings
Revenue
$68.26M
EBIT
-$253.72M
EBITDA
-$244.28M
Free cash flow
-$274.76M
Per share
EPS
-$2.64
Free cash flow per share
-$2.84
Book value per share
$6.01
Revenue per share
$0.71
TBVPS
$8.35
Balance sheet
Total assets
$807.06M
Total liabilities
$226.58M
Debt
$112.3M
Equity
$580.48M
Working capital
$507.64M
Liquidity
Debt to equity
0.19
Current ratio
6.55
Quick ratio
6.53
Net debt/EBITDA
-0.17
Margins
EBITDA margin
-357.9%
Gross margin
100%
Net margin
-371.7%
Operating margin
-412.5%
Efficiency
Return on assets
-28.4%
Return on equity
-38.7%
Return on invested capital
-31.4%
Return on capital employed
-35.5%
Return on sales
-371.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FATE stock price

How has the Fate Therapeutics stock price performed over time
Intraday
2.15%
1 week
13.65%
1 month
13.76%
1 year
-64.22%
YTD
-41.65%
QTD
37.77%

Financial performance

How have Fate Therapeutics's revenue and profit performed over time
Revenue
$68.26M
Gross profit
$68.26M
Operating income
-$281.58M
Net income
-$253.72M
Gross margin
100%
Net margin
-371.7%
FATE's operating income has dropped by 78% year-on-year and by 15% since the previous quarter
The gross profit has increased by 42% year-on-year and by 8% since the previous quarter
FATE's revenue is up by 42% year-on-year and by 8% since the previous quarter
The operating margin has contracted by 25% YoY and by 6% from the previous quarter

Growth

What is Fate Therapeutics's growth rate over time

Valuation

What is Fate Therapeutics stock price valuation
P/E
N/A
P/B
5.68
P/S
48.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
49.13
FATE's EPS is down by 12% year-on-year and by 9% since the previous quarter
FATE's price to book (P/B) is 26% lower than its 5-year quarterly average of 7.7 and 13% lower than its last 4 quarters average of 6.5
The company's equity fell by 23% YoY and by 8% QoQ
The stock's price to sales (P/S) is 65% less than its 5-year quarterly average of 138.6 and 35% less than its last 4 quarters average of 74.2
FATE's revenue is up by 42% year-on-year and by 8% since the previous quarter

Efficiency

How efficient is Fate Therapeutics business performance
The ROE has contracted by 16% from the previous quarter and by 7% YoY
FATE's return on sales is up by 16% year-on-year
The ROIC has contracted by 15% from the previous quarter but it has grown by 3.1% YoY
Fate Therapeutics's return on assets has decreased by 15% QoQ and by 11% YoY

Dividends

What is FATE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FATE.

Financial health

How did Fate Therapeutics financials performed over time
FATE's total assets is down by 21% year-on-year and by 6% since the previous quarter
The company's quick ratio fell by 16% QoQ and by 4.4% YoY
The debt is 81% smaller than the equity
The company's debt to equity rose by 27% YoY and by 6% QoQ
The company's equity fell by 23% YoY and by 8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.